A quantitative systems pharmacology (QSP) model for predicting first-in-human (FIH) dose of bispecific antibody-drug conjugates (BsADC) based on preclinical results

Predicting efficacy of antibody drug conjugate (ADC) combined with aPD-1 x aVEGF bispecific Antibody in Platinum resistant Ovarian Cancer patients using the platform Quantitative Systems Pharmacology (QSP) model

Decoding Differential Response to GLP-1 Receptor Agonists in Type-2 Diabetic and Non-Diabetic Obesity: Insights from an Integrated Model of Glycemia, Weight Loss, and Nausea

Quantitative systems pharmacology guided First-In-Human (FIH) dose recommendation for T-Cell Engagers (TCE): a case study to support model-informed FIH trial design

Designing Smarter ADC Combinations: A QSP Framework for Dose Optimization

Clinical Dose Optimization Of Belantamab Mafodotin For First-In-Human Trial Using A Translational PK-PD Framework

What Drives First-in-Human Dose Escalation in Oncology? A Cross-Modality Analysis of Small Molecules, Monoclonal Antibodies, ADCs, and T-Cell Engagers

ICH M15 Report for a prior regulatory approved MIDD analysis

QSP GUIDED MABEL ESTIMATION FOR T-CELL ENGAGERS : A CASE STUDY ON MODEL-INFORMED FIRST-IN-HUMAN DOSE SELECTION

Mechanistic modeling of efficacy and nausea of GLP-1 receptor agonist (RA) Semaglutide and dual GLP-1/GIPRA Tirzepatide in non-diabetic obese patients

Quantitative Systems Pharmacology guided MABEL estimation for T-cell Engagers (TCE): A case study to support model-informed first-in-human dose selection

Optimal therapeutic combinations for Phase 3 UC trial design- recommendations from a QSP platform model